Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Dr. Suzette Delaloge Receives the Grand Prix de la Recherche Ruban Rose
A medical oncologist at Gustave Roussy and director of the personalised prevention program Interception, Dr. Suzette Delaloge has been honoured by the Ruban Rose Association for her research aimed at developing a saliva test capable of detecting early signs of breast cancer.
Published on
Dr. Suzette Delaloge, an international expert in breast cancer and personalised prevention, received the Grand Prix de la Recherche Ruban Rose on Thursday, January 16, at the French National Assembly.
This prestigious award, endowed with €350,000, supports an innovative research project she is leading. It aims to identify early warning signals, detectable at least three years before the onset of the disease, which could predict the occurrence of breast cancer.
"We will analyse the saliva of 200 women who have developed breast cancer as part of our large international study, MyPeBS, and compare it to the saliva of 200 women with the same initial characteristics but who did not develop the disease," explains Dr. Delaloge. "The goal is to identify a profile of genetic modifications in salivary DNA (including methylation) associated with the development of breast cancer in the following years," she adds.
Saliva tests have the advantage of being non-invasive and cost-effective. Ultimately, this research program aims to develop a saliva-based prevention test focused on breast cancer, which could be implemented across France.
"Like many oncologists, my motivation is intrinsic," says Dr. Delaloge. "What drives us, what fuels these programs, what continuously pushes us to go further is the desire to prevent cancer from occurring, to ensure it is diagnosed earlier, and if cancer does develop, to improve treatments and increase the chances of recovery," she continues.
This project is part of the Interception program, conceived by Dr. Delaloge and launched in 2021. Interception is based on a comprehensive approach to personalised prevention. It has already been applied to several pathways tailored to specific cancer types or risk factors. In 2024, the first Interception pathways were introduced in several partner centres across France, with more set to open in mainland France and overseas territories in 2025.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
